174 related articles for article (PubMed ID: 33433837)
1. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.
Torres-Jiménez J; Esteban-Villarrubia J; García-Abellás P; Cortés-Salgado A; Soria-Rivas A; Gajate-Borau P; Olmedo-García ME; Corral-de la Fuente E; Lage-Alfranca Y; Gómez-Rueda A; Benito-Berlinches A; Gorospe-Sarasua L; Garrido-López P
Clin Transl Oncol; 2021 Jul; 23(7):1474-1480. PubMed ID: 33433837
[TBL] [Abstract][Full Text] [Related]
2. Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival.
Smith H; Easterling R; Ma J; Moodabagil M; Meara A; Owen DH; Crouser E; Singha A; Ho K
Respir Med; 2024 Jun; 227():107640. PubMed ID: 38648910
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
5. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
Gkiozos I; Kopitopoulou A; Kalkanis A; Vamvakaris IN; Judson MA; Syrigos KN
J Thorac Oncol; 2018 Aug; 13(8):1076-1082. PubMed ID: 29763666
[TBL] [Abstract][Full Text] [Related]
6. Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Sagawa T; Sato Y; Nagashima H; Takada K; Takahashi M; Hirakawa M; Hamaguchi K; Tamura F; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Front Immunol; 2023; 14():1203621. PubMed ID: 37492584
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.
Cabanié C; Ammari S; Hans S; Pobel C; Laparra A; Danlos FX; Chanson N; Dolidon S; Seban R; Voisin AL; Pautier P; Romano-Martin P; Even C; Baldini C; Besse B; Albiges L; Boutros C; Routier E; Balleyguier C; De Montpreville VT; Champiat S; Massard C; Robert C; Marabelle A; Mateus C; Lambotte O; Le Pavec J; Michot JM
Eur J Cancer; 2021 Oct; 156():46-59. PubMed ID: 34425404
[TBL] [Abstract][Full Text] [Related]
8. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis.
Kim ST; Pundole X; Dadu R; Lambotte O; Ramos-Casals M; Suarez-Almazor ME
Immunotherapy; 2021 Apr; 13(6):465-475. PubMed ID: 33641345
[TBL] [Abstract][Full Text] [Related]
9. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
10. Sarcoid-like Reactions to Immune Checkpoint Inhibitors.
Torrecilla-Vall-Llossera C; Jucglà Serra A; Molinero Caturla J; Moreno-Vílchez C; Penín Mosquera RM; Marcoval Caus J
Actas Dermosifiliogr; 2024 Jan; 115(1):80-83. PubMed ID: 37482293
[TBL] [Abstract][Full Text] [Related]
11. Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report.
Torres-Zurita A; Vázquez-Montero L; Gallego-López L; Mediano-Rambla MD; de la Cruz-Merino L
Front Immunol; 2023; 14():1150128. PubMed ID: 37781378
[TBL] [Abstract][Full Text] [Related]
12. Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab.
González-Cruz C; Bodet D; Muñoz-Couselo E; García-Patos V
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509865
[TBL] [Abstract][Full Text] [Related]
13. Renal Sarcoidosis-like Reaction Induced by PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Park SD; Kim MS; Han MH; Kim YJ; Jung HY; Choi JY; Cho JH; Park SH; Kim CD; Kim YL; Lim JH
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241223
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy-induced exclusively cutaneous sarcoid-like reaction.
Mazumder A; Mehrmal S; Chaudhry S
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37463781
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma.
Rubio-Rivas M; Moreira C; Marcoval J
Autoimmun Rev; 2020 Aug; 19(8):102587. PubMed ID: 32553612
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer.
Tsunoda A; Mizuno T; Iida S; Uchida K; Yamashita M; Sukeno K; Oka H; Tono Y; Ishihara M; Saito K; Tamaru S; Yamanaka K; Tawara I
Case Rep Oncol Med; 2022; 2022():2709062. PubMed ID: 35127188
[TBL] [Abstract][Full Text] [Related]
18. Sarcoid-like reactions in patients receiving modern melanoma treatment.
Dimitriou F; Frauchiger AL; Urosevic-Maiwald M; Naegeli MC; Goldinger SM; Barysch M; Franzen D; Kamarachev J; Braun R; Dummer R; Mangana J
Melanoma Res; 2018 Jun; 28(3):230-236. PubMed ID: 29485531
[TBL] [Abstract][Full Text] [Related]
19. Sarcoid-like reaction in cases treated by checkpoint inhibitors.
Paydas S
Med Oncol; 2021 Feb; 38(3):29. PubMed ID: 33598792
[TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
